MRTX — Mirati Therapeutics Share News
0.000.00%
Last trade - 00:00- $4.12bn
- $3.15bn
- $12.44m
US FDA turns down Amgen lung cancer drug Lumakras for full approval (updated)
US FDA turns down Amgen lung cancer drug Lumakras for full approval
Brief: Mirati Stockholders Voted 'For' Proposal To Adopt Deal Between Co, Bristol-Myers Squibb
Mirati's lung cancer drug gets EU's regulatory backing (updated)
EU regulators back Mirati's lung cancer drug
Mirati Therapeutics Inc expected to post a loss of $2.84 a share - Earnings Preview
Brief: Kura Oncology And Mirati Therapeutics Enter Into Clinical Collaboration
Bristol Myers says it needs another year to hit target for new drugs (updated)
Bristol Myers says it needs another year to hit target for new drugs
Risky biotech M&A therapy will heal more fractures
Brief: Mirati Presents Late-Breaking Results Evaluating The Combination Of Adagrasib And Pembrolizumab In First-Line Non-Small Cell Lung Cancer (Nsclc)
Brief: Upon Termination Of Deal Mirati Therapeutics Will Be Required To Pay Bristol-Myers Squibb Termination Fee
U.S. RESEARCH ROUNDUP-Corning, Juniper Networks, Mirati Therapeutics
U.S. STOCKS ON THE MOVE-National Western Life, Imperial Petroleum, Natgas firms
Refinitiv Newscasts - Trading at Noon: markets rocked on fears of escalation in Mid East violence
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Illumina, AnaptysBio, Royal Caribbean Group
U.S. STOCKS ON THE MOVE-Gold Miners, Oil companies, Big Tech
Mirati Therapeutics falls after buyout deal by Bristol-Myers Squibb